A phase I study of intralesional administration of an adenovirus vector expressing the HSV-1 thymidine kinase gene (AdV.RSV-TK) in combination with escalating doses of ganciclovir in patients with cutaneous metastatic malignant melanoma

Human Gene Therapy

Volumn 11, Issue 3, 2000, Pages 487-503

  Morris, John C ^a   Ramsey, W Jay ^a   Wildner, Oliver ^a   Muslow, Harry A ^a   Aguilar Cordova, Estuardo ^a   Blaese, R Michael ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; THYMIDINE KINASE; VIRUS VECTOR;

ADENOVIRUS; ARTICLE; BLOOD TOXICITY; CLINICAL TRIAL; GENE; HERPES SIMPLEX VIRUS 1; HUMAN; MELANOMA; PHASE 1 CLINICAL TRIAL; PHLEBITIS; SKIN METASTASIS; UREMIA;

ADENOVIRIDAE; ANTIVIRAL AGENTS; FEMALE; GANCICLOVIR; GENE THERAPY; GENETIC VECTORS; HERPESVIRUS 1, HUMAN; HUMANS; MALE; MELANOMA; SKIN NEOPLASMS; THYMIDINE KINASE;

ADENOVIRIDAE; HERPES; HUMAN HERPESVIRUS 1;

EID: 0034628523     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430340050015950     Document Type: Article

References (58)

1. ACTG/SOCA. (1996). Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The Cytomegalovirus Retreatment Trial. The Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Arch. Ophthalmol. 114(1), 23-33.
2. ANDERSON, C.M., BUZAID, A.C., and LEGHA, S.S. (1995). Systemic treatments for advanced cutaneous melanoma. Oncology (Huntingt). 9(11), 1149-58; discussion 1163-4, 1167-8.
3. BALCH, C.M., SOONG, S.J., MURAD, T.M., INGALLS, A.L., and MADDOX, W.A. (1981a). A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II). Ann. Surg. 193(3), 377-88.
4. BALCH, C.M., SOONG, S.J., MURAD, T.M., SMITH, J.W., MADDOX, W.A., and DURANT, J.R. (1983b). A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J. Clin. Oncol. 1(2), 126-34.
5. BALZARINI, J., BOHMAN, C., WALKER, R.T., and DE CLERCQ, E. (1994). Comparative cytostatic activity of different antiherpetic drugs against herpes simplex virus thymidine kinase gene-transfected tumor cells. Mol. Pharmacol. 45(6), 1253-8.
6. BARBA, D., HARDIN, J., SADELAIN, M., and GAGE, F.H. (1994). Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc. Natl. Acad. Sci. USA 91(10), 4348-52.
7. BAUER, R., KOPALD, K., LEE, J., WONG, J., and MORTON, D. (1990). Long-term results of intralesional BCG for locally advanced recurrent melanoma. Proc. Amer. Soc. Clin. Oncol. 9, 276.
8. BI, W.L., PARYSEK, L.M., WARNICK, R., and STAMBROOK, P.J. (1993). In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Hum. Gene Ther. 4(6), 725-31.
9. BIRON, K.K., STANAT, S.C., SORRELL, J.B., FYFE, J.A., KELLER, P.M., LAMBE, C.U., and NELSON, D.J. (1985). Metabolic activation of the nucleoside analog 9-[(2-hydroxy-1- (hydroxymethyl)ethoxy]methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus. Proc. Natl. Acad. Sci. USA 82(8), 2473-7.
10. BLAESE, R.M., CULVER, K.W., MILLER, A.D., CARTER, C.S., FLEISHER, T., CLERICI, M., SHEARER, G., CHANG, L., CHIANG, Y., TOLSTOSHEV, P., and et al. (1995b). T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 270(5235), 475-80.
11. BLAESE, R.M., ISHII-MORITA, H., MULLEN, C., RAMSEY, J., RAM, Z., OLDFIELD, E., and CULVER, K. (1994a). In situ delivery of suicide genes for cancer treatment. Eur. J. Cancer 8(3), 1190-3.
12. BRENNER, M.K., RILL, D.R., HOLLADAY, M.S., HESLOP, H.E., MOEN, R.C., BUSCHLE, M., KRANCE, R.A., SANTANA, V.M., ANDERSON, W.F., and IHLE, J.N. (1993). Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients. Lancet 342(8880), 1134-7.
13. BRODY, S.L., and CRYSTAL, R.G. (1994). Adenovirus-mediated in vivo gene transfer. Ann. N.Y. Acad. Sci. 716, 90-101; discussion 101-3.
14. BUHLES, W.C. (1991b). Clinical safety of intravenous ganciclovir. In Ganciclovir Therapy for Cytomegalovirus Infection, S.A. Spector, ed., (Marcel-Dekker, Inc., New York), pp. 31-69.
15. BUHLES, W.C., JR., MASTRE, B.J., TINKER, A.J., STRAND, V., and KORETZ, S.H. (1988a). Ganciclovir treatment of life-or sight-threatening cytomegalovirus infection: experience in 314 immunocompromised patients. Rev. Infect. Dis. 10 Suppl 3, S495-506.
16. CHEN, S.H., SHINE, H.D., GOODMAN, J.C., GROSSMAN, R.G., and WOO, S.L.C. (1994). Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc. Natl. Acad. Sci. USA 91(8), 3054-7.
17. CLARK, W.H., JR., ELDER, D.E., GUERRY, D.T., BRAITMAN, L.E., TROCK, B.J., SCHULTZ, D., SYNNESTVEDT, M., and HALPERN, A.C. (1989). Model predicting survival in stage I melanoma based on tumor progression [see comments]. J. Natl. Cancer Inst. 81(24), 1893-904.
18. COLOMBO, B.M., BENEDETTI, S., OTTOLENGHI, S., MORA, M., POLLO, B., POLI, G., and FINOCCHIARO, G. (1995). The "bystander effect": association of U-87 cell death with ganciclovir-mediated apoptosis of nearby cells and lack of effect in athymic mice. Hum. Gene Ther. 6(6), 763-72.
19. CROMBIE, I.K. (1979). Racial differences in melanoma incidence. Br. J. Cancer 40(2), 185-93.
20. CULVER, K.W., RAM, Z., WALLBRIDGE, S., ISHII, H., OLDFIELD, E.H., and BLAESE, R.M. (1992). In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors [see comments]. Science 256(5063), 1550-2.
21. DEISSEROTH, A.B., ZU, Z., CLAXTON, D., HANANIA, E.G., FU, S., ELLERSON, D., GOLDBERG, L., THOMAS, M., JANICEK, K., ANDERSON, W.F., and et al. (1994). Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood. 83(10), 3068-76.
22. EVERSON, T.C., and COLE, W.M. (1966). Spontaneous regression of malignant melanoma. In Spontaneous Regression of Cancer, T.C. Everson and W.M. Cole, eds., (W.B. Saunders, Philadelphia, PA), pp. 164-215.
23. FAULDS, D., and HEEL, R.C. (1990). Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs 39(4), 597-638.
24. FLETCHER, C., SAWCHUK, R., CHINNOCK, B., DE MIRANDA, P., and BALFOUR, H.H., JR. (1986). Human pharmacokinetics of the antiviral drug DHPG. Clin. Pharmacol. Ther. 40(3), 281-6.
25. GARBE, C. (1993). Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma. Melanoma Res. 3(4), 291-9.
26. GHUSSEN, F., KRUGER, I., GROTH, W., and STUTZER, H. (1988). The role of regional hyperthermic cytostatic perfusion in the treatment of extremity melanoma. Cancer 61(4), 654-9.
27. GINGRAS, M.C., AREVALO, P., and AGUILAR-CORDOVA, E. (1996). Potential salmon sperm origin of the E3 region insert of the adenovirus 5 d1309 mutant. Cancer Gene Ther. 3(3), 151-4.
28. GLASS, A.G., and HOOVER, R.N. (1989). The emerging epidemic of melanoma and squamous cell skin cancer [see comments]. JAMA 262(15), 2097-100.
29. GROSSBERG, H.S., BONNEM, E.M., and BUHLES, W.C., JR. (1989). GM-CSF with ganciclovir for the treatment of CMV retinitis in AIDS [letter]. N. Engl. J. Med. 320(23), 1560.
30. ISHII-MORITA, H., AGBARIA, R., MULLEN, C.A., HIRANO, H., KOEPLIN, D.A., RAM, Z., OLDFIELD, E.H., JOHNS, D.G., and BLAESE, R.M. (1997). Mechanism of 'bystander effect' killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment. Gene Ther. 4(3), 244-51.
31. JACOBSON, M.A. (1997). Treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome [published erratum appears in N. Engl. J. Med. 1997 Oct 2;337(14):1019]. N. Engl. J. Med. 337(2), 105-14.
32. JOLLY, D. (1994). Viral vector systems for gene therapy. Cancer Gene Ther. 1(1), 51-64.
33. KATO, K., YOSHIDA, J., MIZUNO, M., SUGITA, K., and EMI, N. (1994). Retroviral transfer of herpes simplex thymidine kinase gene into glioma cells causes targeting of ganciclovir cytotoxic effect. Neurol. Med. Chir. (Tokyo). 34(6), 339-44.
34. KIRKWOOD, J.M., STRAWDERMAN, M.H., ERNSTOFF, M.S., SMITH, T.J., BORDEN, E.C., and BLUM, R.H. (1996). Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684 [see comments]. J. Clin. Oncol. 14(1), 7-17.
35. KNOWLES, M.R., HOHNEKER, K.W., ZHOU, Z., OLSEN, J.C., NOAH, T.L., HU, P.C., LEIGH, M.W., ENGELHARDT, J.F., EDWARDS, L.J., JONES, K.R., and et al. (1995). A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis [see comments]. N. Engl. J. Med. 333(13), 823-31.
36. LANDIS, S.H., MURRAY, T., BOLDEN, S., and WINGO, P. (1998). Cancer statistics, 1998. CA: Cancer. J. Clin. 48(1), 6-30.
37. LASKIN, O.L., CEDERBERG, D.M., MILLS, J., ERON, L.J., MILDVAN, D., and SPECTOR, S.A. (1987). Ganciclovir for the treatment and suppression of serious infections caused by cytomegalovirus. Am. J. Med. 83(2), 201-7.
38. MAR, E.C., CHENG, Y.C., and HUANG, E.S. (1983). Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on human cytomegalovirus replication in vitro. Antimicrob. Agents Chemother. 24(4), 518-21.
39. MOOLTEN, F.L. (1986a). Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 46(10), 5276-81.
40. MOOLTEN, F.L., and WELLS, J.M. (1990b). Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J. Natl. Cancer Inst. 82(4), 297-300.
41. MULLEN, C.A., KILSTRUP, M., and BLAESE, R.M. (1992). Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine : a negative selection system. Proc. Natl. Acad. Sci. USA 89(1), 33-7.
42. NATHANSON, L., and JILANI, S. (1993). Chemotherapy of malignant melanoma. In Current Research and Clinical Management of Melanoma., L. Nathanson, ed., (Kluwer Academic Publishers, Boston), pp. 335-354.
43. NYBERG-HOFFMAN, C., SHABRAM, P., LI, W., GIROUX, D., and AGUILAR-CORDOVA, E. (1997). Sensitivity and reproducibility in adenoviral infectious titer determination. Nat. Med. 3(7), 808-11.
44. OLDFIELD, E.H., RAM, Z., CULVER, K.W., BLAESE, R.M., DEVROOM, H.L., and ANDERSON, W.F. (1993). Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum. Gene Ther. 4(1), 39-69.
45. PEREZ-CRUET, M.J., TRASK, T.W., CHEN, S.H., GOODMAN, J.C., WOO, S.L.C., GROSSMAN, R.G., and SHINE, H.D. (1994). Adenovirus-mediated gene therapy of experimental gliomas. J. Neurosci. Res. 39(4), 506-11.
46. RAM, Z., CULVER, K.W., OSHIRO, E.M., VIOLA, J.J., DEVROOM, H.L., OTTO, E., LONG, Z., CHIANG, Y., MCGARRITY, G.J., MUUL, L.M., KATZ, D., BLAESE, R.M., and OLDFIELD, E.H. (1997). Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells [see comments]. Nat. Med. 3(12), 1354-61.
47. RIGEL, D.S., KOPF, A.W., and FRIEDMAN, R.J. (1987). The rate of malignant melanoma in the United States: are we making an impact? J. Am. Acad. Dermatol. 17(6), 1050-3.
48. ROSENBERG, S.A., LOTZE, M.T., YANG, J.C., TOPALIAN, S.L., CHANG, A.E., SCHWARTZENTRUBER, D.J., AEBERSOLD, P., LEITMAN, S., LINEHAN, W.M., SEIPP, C.A., and et al. (1993). Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer [published erratum appears in J. Natl. Cancer. Inst. 1993 Jul 7:85(13):1091]. J. Natl. Cancer Inst. 85(8), 622-32.
49. ROTH, J.A., and CRISTIANO, R.J., (1997). Gene therapy for cancer: what have we done and where are we going? J. Natl. Cancer. Inst. 89(1), 21-39.
50. SALOPEK, T.G., MARGHOOB, A.A., SLADE, J.M., RAO, B., RIGEL, D.S., KOPF, A.W., and BART, R.S. (1995). An estimate of the incidence of malignant melanoma in the United States. Based on a survey of members of the American Academy of Dermatology. Dermatol. Surg. 21(4), 301-5.
51. SCARDINO, P.T., ADLER, H.L., HERMAN, J.R., WOO, S.L.C., AGUILAR-CORDOVA, E., TIMME, T.L., and THOMPSON, T.C. (1998). Herpes simplex thymidine-kinase (HSV-tk) mediated gene therapy is safe and active against locally recurrent prostate cancer after irradiation therapy. Proc. Amer. Soc. Clin. Oncol. 17, 308a.
52. SHAH, M.R. (1997). Tumor immunity following adenovirus mediated herpes simplex thymidine-kinase gene transfer to experimental rat gliomas. Doctor of Philosophy Dissertation, Virginia Commonwealth University, Richmond.
53. SHEPP, D.H., DANDLIKER, P.S., DE MIRANDA, P., BURNETTE, T.C., CEDERBERG, D.M., KIRK, L.E., and MEYERS, J.D. (1985). Activity of 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine in the treatment of cytomegalovirus pneumonia. Ann. Intern. Med. 103(3), 368-73.
54. SOMMADOSSI, J.P., BEVAN, R., LING, T., LEE, F., MASTRE, B., CHAPLIN, M.D., NERENBERG, C., KORETZ, S., and BUHLES, W.C., JR. Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function. Rev. Infect. Dis. 10(suppl 3), S507-13, 1998.
55. STADELMAN, W.K., RAPAPORT, D.P., SOONG, S.-J., REITGEN, D.S., BUZAID, A.C., and BLACH, C.M. (1998). Prognostic clinical and pathological features. In Cutaneous Melanoma, C.M. Balch, A.N. Houghton, A.J. Sober, and S.-J. Soong, eds., (Quality Medical Publishing, St. Louis), pp. 11-32.
56. STERMAN, D.H., TREAT, J., LITZKY, L.A., AMIN, K.M., COONROD, L., MOLNAR-KIMBER, K., RECIO, A., KNOX, L., WILSON, J.M., ALBELDA, S.M., and KAISER, L.R. (1998). Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum. Gene Ther. 9(7), 1083-92.
57. TAKAMIYA, Y., SHORT, M.P., EZZEDDINE, Z.D., MOOLTEN, F.L., BREAKEFIELD, X.O., and MARTUZA, R.L. (1992). Gene therapy of malignant brain tumors: a rat glioma line bearing the herpes simplex virus type 1-thymidine kinase gene and wild type retrovirus kills other tumor cells. J. Neurosci. Res. 33(3), 493-503.
58. VILE, R.G., NELSON, J.A., CASTLEDEN, S., CHONG, H., and HART, I.R. (1994). Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res. 54(23), 6228-34.